ARCH Venture Management, LLC
CIK
1274403
Location
CHICAGO, IL
Portfolio Value
Small
$677,097,730
Diversification
Moderately concentrated
Filing Date
Global Rank
#2,225
/ 8,604
▲ 89
· as of Mar 2026
Top Industry
Biotechnology
99.3%
3Y Alpha vs SPY
+9.3%
Period ended 3 months ago
Filed May 15, 2026 · 55d
20 quarters · since Mar 2020
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+120.3%
SPY
+76.5%
Annualised alpha
+9.3%
Max drawdown
−58.8%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
10 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
18.2%
−8.0 pts
Top 5
85.4%
−2.4 pts
Top 10
100.0%
0.0 pts
HHI
1,568
Moderately concentrated−163
Portfolio Trend
20 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $677,097,730 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | +488,090 | 3,247,162 | $65,138,069 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| GENB | Generate Biomedicines, Inc. | 1,944,426 | $24,305,325 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
10 positions ·
$677,097,730 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Held | 4,120,053 | $122,983,582 | 18.16% | |
| RAPP |
Rapport Therapeutics, Inc.
Healthcare
|
Held | 3,728,738 | $116,672,212 | 17.23% | |
| VIR |
Vir Biotechnology, Inc.
Healthcare
|
Held | 12,916,663 | $115,733,300 | 17.09% | |
| ERAS |
Erasca, Inc.
Healthcare
|
Reduced | 7,091,557 | $114,741,392 | 16.95% | |
| BEAM |
Beam Therapeutics Inc.
Healthcare
|
Held | 4,540,132 | $108,191,345 | 15.98% | |
| LYEL |
Lyell Immunopharma, Inc.
Healthcare
|
Added | 3,247,162 | $65,138,069 | 9.62% | |
| GENB |
Generate Biomedicines, Inc.
Healthcare
|
NEW | 1,944,426 | $24,305,325 | 3.59% | |
| TXG |
10x Genomics, Inc.
Healthcare
|
Reduced | 217,834 | $4,624,615 | 0.68% | |
| GOSS |
Gossamer Bio, Inc.
Healthcare
|
Held | 8,055,916 | $2,650,396 | 0.39% | |
| QTTB |
Q32 Bio Inc.
Healthcare
|
Held | 320,482 | $2,057,494 | 0.30% |